Thu, Apr 24, 2014, 6:49 AM EDT - U.S. Markets open in 2 hrs 41 mins


% | $
Quotes you view appear here for quick access.

Life Technologies Corporation Message Board

vaniganti 4 posts  |  Last Activity: Feb 8, 2014 9:21 PM Member since: Jan 22, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I am not an expert hepatologist as some on the board claim, nor I am a researcher, but I am the gate keeper, the primary care doctor. Of all the diseases we worry about, NASH is a fringe disease just like TMJ disease or Fibromyalgia. I cant remember the last time I referred any body for NASH to a hepatologist in 20 yrs. Definitely there is more awareness now, because thanks to drug companies we are constantly searching for new diseases and drugs to treat them. Who ever heard of treating neuropathies with until Lyrica became available.
    But beware before you all predict everybody will be treated for NASH. It is a fringe disease as far as we are concerned. I havent seen a single case of Cirrhosis from NASH in my practice. So its a novel research that may lead to better understanding of diseases but not exactly LIPITOR as yet.

  • Reply to

    Sold more @ $345

    by coolfred1999 Feb 7, 2014 2:03 PM
    vaniganti vaniganti Feb 8, 2014 3:38 PM Flag

    I didnt short yet. either I will short at 372 or 338, I want to know it reached its peak or is on its way down

  • Reply to

    I am so Stupid

    by ben_bertanked_me Feb 7, 2014 3:37 PM
    vaniganti vaniganti Feb 8, 2014 3:35 PM Flag

    well when they go to 860,324 dollars a share you would have made an oodles

  • Reply to

    I am so Stupid

    by ben_bertanked_me Feb 7, 2014 3:37 PM
    vaniganti vaniganti Feb 8, 2014 3:34 PM Flag

    what about me, I sold my 300 march calls that I bought for 32.60 for for 48.60, and they went beyond 60.

76.040.00(0.00%)Feb 3 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.